Charles Witherspoon
Known title: VP & TreasurerCIK: 0001731739
Associated companies
Transaction History
| WST | ▲ Buy | Option Exercise | 60 | — | 2/20/2026 | View on chart |
| WST | ▼ Sell | Tax Withholding | 22 | $5K | 2/20/2026 | View on chart |
| WST | ▲ Buy | Grant | 116 | $0 | 2/17/2026 | View on chart |
| WST | ▼ Sell | Tax Withholding | 42 | $10K | 2/17/2026 | View on chart |
| WST | ▲ Buy | Option Exercise | 66 | $14K | 2/18/2025 | View on chart |
| WST | ▼ Sell | Tax Withholding | 23 | $5K | 2/18/2025 | View on chart |
| WST | ▲ Buy | Option Exercise | 478 | $83K | 10/29/2024 | View on chart |
| WST | ▼ Sell | Open Market | 225 | $70K | 10/29/2024 | View on chart |
| WST | ▼ Sell | Open Market | 478 | $148K | 10/29/2024 | View on chart |
| WST | ▲ Buy | Option Exercise | 529 | $54K | 8/19/2024 | View on chart |
| WST | ▼ Sell | Open Market | 500 | $150K | 8/19/2024 | View on chart |
| WST | ▼ Sell | Open Market | 529 | $159K | 8/19/2024 | View on chart |
| WST | ▲ Buy | Option Exercise | 2,019 | $207K | 2/28/2024 | View on chart |
| WST | ▼ Sell | Open Market | 2,019 | $724K | 2/28/2024 | View on chart |
| WST | ▲ Buy | Grant | 144 | $0 | 2/20/2024 | View on chart |
| WST | ▲ Buy | Option Exercise | 594 | $103K | 10/31/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 596 | $163K | 10/31/2023 | View on chart |
| WST | ▼ Sell | Open Market | 594 | $192K | 10/31/2023 | View on chart |
| WST | ▼ Sell | Open Market | 596 | $192K | 10/31/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 840 | $86K | 8/9/2023 | View on chart |
| WST | ▼ Sell | Open Market | 1,680 | $666K | 8/9/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 840 | $146K | 8/9/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 1,000 | $103K | 5/30/2023 | View on chart |
| WST | ▼ Sell | Open Market | 1,000 | $343K | 5/30/2023 | View on chart |
| WST | ▲ Buy | Grant | 407 | $125K | 2/21/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally
West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.